Table 2.
Treatments utilized for HA-AKI, CA-AKI, and no-AKI groups.
| Patients, no. (%) | ||||
|---|---|---|---|---|
| HA-AKI | CA-AKI | No AKI | p | |
| (n = 308) | (n = 295) | (n = 721) | ||
| Invasive mechanical ventilation | 99 (32.1%) | 114 (38.6%) | 17 (2.4%) | b, c |
| Noninvasive mechanical ventilation | 37 (12.0%) | 59 (20.0%) | 30 (4.2%) | a, b, c |
| Anticoagulants | ||||
| Prophylactic | 153 (49.7%) | 172 (58.3%) | 212 (29.4%) | a, b, c |
| Therapeutic | 86 (27.9%) | 87 (29.5%) | 59 (8.2%) | b, c |
| Steroids | 99 (32.1%) | 119 (40.3%) | 69 (9.6%) | a, b, c |
| Renal replacement therapy | ||||
| Continuous renal replacement therapy | 5 (1.6%) | 5 (1.7%) | 0 | ns |
| Hemodialysis | 29 (9.4%) | 22 (7.5%) | 0 | ns |
| Both continuous renal replacement therapy and hemodialysis | 16 (5.2%) | 2 (0.7%) | 0 | a |
Group comparison of categorical variables in frequencies and percentages used χ2 test or Fisher exact tests. p < 0.05 for abetween CA-AKI and HA-AKI, bbetween HA-AKI and no AKI, and cbetween CA-AKI and no AKI. ns, not significant between any pairs.